178 related articles for article (PubMed ID: 34596753)
1. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.
Yamashige D; Hosaka T; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2021 Nov; 56(11):1008-1021. PubMed ID: 34596753
[TBL] [Abstract][Full Text] [Related]
2. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Suzuki F; Sezaki H; Hosaka T; Suzuki Y; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
Hepatol Res; 2021 Apr; 51(4):503-508. PubMed ID: 33462964
[TBL] [Abstract][Full Text] [Related]
3. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Buti M; Marcos-Fosch C; Esteban R
Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
8. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
9. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
10. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
Yamada S; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Uemura H; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mizuno S; Mochida S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38517681
[TBL] [Abstract][Full Text] [Related]
11. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
[TBL] [Abstract][Full Text] [Related]
12. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW
Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175
[TBL] [Abstract][Full Text] [Related]
14. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
17. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
18. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Lim YS; Seto WK; Kurosaki M; Fung S; Kao JH; Hou J; Gordon SC; Flaherty JF; Yee LJ; Zhao Y; Agarwal K; Lampertico P
Aliment Pharmacol Ther; 2022 Apr; 55(8):921-943. PubMed ID: 35178711
[TBL] [Abstract][Full Text] [Related]
19. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Uchida Y; Nakao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Motoya D; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
J Med Virol; 2020 Mar; 92(3):329-338. PubMed ID: 31777965
[TBL] [Abstract][Full Text] [Related]
20. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]